SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Renin-Angiotensin-Aldosterone System
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Sagnella, G. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sagnella, G. A
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Review: Vasopeptidase inhibitors

Giuseppe A Sagnella

Blood Pressure Unit, St George's Hospital Medical School, Cranmer Terrace, London, SW17 0RE, UK, g.sagnella@ sghms.ac.uk

Vasopeptidase inhibitors are a new class of drugs that have dual inhibitory effects on two key enzymes involved in the metabolism of vasoactive peptides. Essentially, they inhibit angiotensin-converting enzyme (ACE), thereby blocking the generation of angiotensin II (Ang II); at the same time they prevent the breakdown of natriuretic peptides by the enzyme neutral endopeptidase. The combination of reduction of Ang II on a background of increased natriuretic peptide activity has several potential advantages for the treatment of cardiovascular and renal disease and in particular, hypertension and congestive heart failure (CHF). Several vasopeptidase inhibitors, such as sampatrilat, fasidotril, gemopatrilat and omapatrilat (VanlevTM, the most clinically developed vasopeptidase inhibitor to date) are under intensive clinical investigation. Recent clinical trials have demonstrated effective antihypertensive activity in hypertension, independent of age, renin and salt status or ethnic origin, and have also highlighted the potential for vasopeptidase inhibition as a new therapeutic modality for the treatment of CHF. Moreover, ongoing research suggests that this new class of drugs may be an important approach, not only for the treatment of hypertension and of conditions associated with overt volume overload but also for ischaemic heart disease.

Key Words: natriuretic peptides • vasopeptidase inhibitors • angiotensin II • clinical trials

References

  • Sagnella GA Atrial natriuretic peptide mimetics and vasopeptidase inhibitors. Cardiovasc Res 2001;51:416-28.[Abstract/Free Full Text]
  • Lewin ER, Gardner DG, Samson WK Natriuretic peptides. N Engl J Med 1998;339:321-8.[Free Full Text]
  • Erdos EG, Skidgel RA Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. Faseb J 1989;3:145-51.[Abstract]
  • Roques BP, Beaumont A. Neutral endopeptidase-24.11 inhibitors: from analgesics to antihypertensives? TIPS 1990;11: 245-9.[Medline] [Order article via Infotrieve]
  • Roques BP, Noble F., Dauge V., Fournie-Zaluski MC, Beaumont A. Neutral endopeptidase 24.11: structure, inhibition and experimental clinical pharmacology. Pharmacol Rev 1993;45:87-146.[Web of Science][Medline] [Order article via Infotrieve]
  • Wilkins MR, Unwin RJ, Kenny AJ Endopeptidase-24.11 and its inhibitors: Potential therapeutic agents for edematous disorders and hypertension. Kidney Int 1993;43:273-85.[Web of Science][Medline] [Order article via Infotrieve]
  • Richards M., Espiner E., Frampton C. et al. Inhibition of endopeptidase EC 24.11 in humans. Renal and endocrine effects. Hypertension 1990;16:269-76.[Abstract/Free Full Text]
  • JardineAG, Connell JM, Northridge D. et al.The atriopeptidase inhibitor UK 69,578 increases atrial natriuretic factor and causes a natriuresis in normal humans. Am J Hypertens 1990;3:661-7.[Web of Science][Medline] [Order article via Infotrieve]
  • O'Connell JE, Jardine AG, Davies DL, McQueen J., Connell JM Renal and hormonal effects of chronic inhibition of neutral endopeptidase (EC 3.4.24.11) in normal man. Clin Sci 1993;85:19-26.[Web of Science][Medline] [Order article via Infotrieve]
  • Sagnella GA, Markandu ND, Buckley MG et al. Hormonal and renal responses to neutral endopeptidase inhibition in normal humans on a low and on a high sodium intake. Eur J Clin Invest 1995;25:165-70.[Web of Science][Medline] [Order article via Infotrieve]
  • Westheim AS, Bostrom P., Christensen CC, Parikka H., Rykke EO, Toivonen L. Hemodynamic and neuroendocrine effects for candoxatril and frusemide in mild stable chronic heart failure. J Am Coll Cardiol 1999;34:1794-801.[Abstract/Free Full Text]
  • Northridge DB, Newby DE, Rooney E., Norrie J., Dargie HJ Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure. Am Heart J 1999;138:1149-57.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Richards AM, Wittert GA, Crozier IG et al. Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II. J Hypertens 1993;11:407-16.[Web of Science][Medline] [Order article via Infotrieve]
  • Ando S., Rahman MA, Butler GC, Senn BL, Floras JS Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin. Hypertension 1995;26: 1160-6.[Abstract/Free Full Text]
  • Seymour AA, Swerdel JN, Abboa-Offei B. Antihypertensive activity during inhibition of neutral endopeptidase and angiotensin converting enzyme. J Cardiovasc Pharmacol 1991;17:456-65.[Web of Science][Medline] [Order article via Infotrieve]
  • Pham I., Gonzalez W., el Amrani AI et al. Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension. J Pharmacol Exp Ther 1993;265:1339-47.[Abstract/Free Full Text]
  • Tikkanen T.,Tikkanen I., Rockell MD et al. Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus. Hypertension 1998;32:778-85.[Abstract/Free Full Text]
  • Margulies KB, Perrella MA, McKinley LJ, Burnett JC, Jr. Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure. J Clin Invest 1991;88:1636-42.[Web of Science][Medline] [Order article via Infotrieve]
  • Seymour AA, Asaad MM, Lanoce VM, Langenbacher KM, Fennell SA, Rogers WL Systemic hemodynamics, renal function and hormonal levels during inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in conscious dogs with pacing-induced heart failure. J Pharmacol Exp Ther 1993;266:872-83.[Abstract/Free Full Text]
  • Stergiou GS, Hannah JA, Bevan EG et al. Combined atriopeptidase inhibition and angiotensin converting enzyme inhibition in hypertensive patients(abstract). J Hypertens 1994;12: 1310-11.
  • Favrat B., Burnier M., Nussberger J. et al. Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension. J Hypertens 1995;13:797-804.[Web of Science][Medline] [Order article via Infotrieve]
  • Gros C., Noel N., Souque A. et al. Mixed inhibitors of angiotensin-converting enzyme (EC 3.4.15.1) and enkephalinase (EC 3.4.24.11):rational design, properties, and potential cardiovascular applications of glycopril and alatriopril. Proc Natl Acad Sci USA 1991;88:4210-14.[Abstract/Free Full Text]
  • Intengan HD, Schiffrin EL Vasopeptidase inhibition has potent effects on blood pressure and resistance arteries in stroke-prone spontaneously hypertensive rats. Hypertension 2000;35:1221-5.[Abstract/Free Full Text]
  • Trippodo NC, Robl JA, Asaad MM, Fox M., Panchal BC, Schaeffer TR Effects of omapatrilat in low, normal, and high renin experimental hypertension. Am J Hypertens 1998;11: 363-72.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Troughton RW, Rademaker MT, Powell JD et al. Beneficial renal and hemodynamic effects of omapatrilat in mild and severe heart failure. Am J Hypertens 2000;13:1110-16.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Massien C.,Azizi M., Guyene TT, Vesterqvist O., Mangold B., Menard J. Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans. Clin Pharmacol Ther 1999;65:448-59.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Lainchbury JG, Burnett Jr JC The cardiac hormone atrial natriuretic peptide mediates hemodynamic actions of dual enzyme inhibition in early left ventricular dysfunction. Circulation 1999;100:I-438(abstract).
  • Raut R., Rouleau JL, Blais CJ et al. Bradykinin metabolism in the postinfarcted rat heart: role of ACE and neutral endopeptidase 24.11. Am J Physiol 1999;276:H1769-79.[Web of Science][Medline] [Order article via Infotrieve]
  • Vesterqvist O., Campese VM, Liao W. et al. Omapatrilat increases plasma concentration of adrenomedullin in salt-sensitive hypertensives. Am J Hypertens 2000;13(No 4, part 2):125A;A040(abstract).
  • Rousso P., Buclin T., Nussberger J. et al. Effects of a dual inhibitor of angiotensin converting enzyme and neutral endopeptidase, MDL 100, 240, on endocrine and renal functions in healthy volunteers. J Hypertens 1999;17:427-37.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Campese VM, Lasseter KC, Ferrario CM et al. Omapatrilat versus lisinopril: efficacy and neurohormonal profile in salt-sensitive hypertensive patients. Hypertension 2000;38:1342-8.[CrossRef]
  • Liao W., Delaney CL, Catanzariti PA, Meier A., Swanson BN, Uderman HD Omapatrilat is not a diuretic: single-and multiple-dose analysis of the urinary excretion of sodium. Am J Hypertens 2000;13:133A(abstract).
  • Cataliotti A., Boerrigter G., Chen HH et al. Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failure. Circulation 2002;105:639-44.[Abstract/Free Full Text]
  • McClean DR, Ikram H., Garlick AH, Richards AM, Nicholls MG, Crozier IG The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure. J Am Coll Cardiol 2000;36: 479-86.[Abstract/Free Full Text]
  • Norton GR, Woodiwiss AJ, Hartford C. et al. Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects.AmJHypertens 1999;12:563-71.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Robl JA, Sulsky R., Sieber-McMaster E. et al. Vasopeptidase inhibitors: incorporation of a geminal and spirocyclic substituted azepinones in mercaptoacyl dipeptides. J Med Chem 1999;42:305-11.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • French JF, Flynn GA, Giroux EL et al. Characterization of a dual inhibitor of angiotensin I-converting enzyme and neutral endopeptidase. J Pharmacol Exp Ther 1994;268:180-6.[Abstract/Free Full Text]
  • Laurent S., Boutouyrie P., Azizi M. et al. Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and angiotensin-converting enzyme, in rats and humans. Hypertension 2000;35:1148-53.[Abstract/Free Full Text]
  • Marie C., Mossiat C., Gros C., Schwartz JC, Lecomte JM, Bralet J. Effect of long-term therapy with fasidotril, a mixed inhibitor of neprilysin and angiotensin-converting enzyme (ACE), on survival of rats after myocardial infarction. Cardiovasc Res 1999; 41:544-53.[Abstract/Free Full Text]
  • Bani M., Colantoni A., Guillaume M., Macchi F., Moroni G., Persiani S. A double-blind, placebo-controlled study to assess tolerability, pharmacokinetics and preliminary pharmacodynamics of single escalating doses of Z13752A, a novel dual inhibitor of the metalloproteases ACE and NEP, in healthy volunteers. Br J Clin Pharmacol 2000;50:338-49.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Rastegar MA, Marchini F., Morazzoni G., Vegh A., Papp JG, Parratt JR The effects of Z13752A, a combined ACE/NEP inhibitor, on responses to coronary artery occlusion; a primary protective role for bradykinin. Br J Pharmacol 2000;129:671-80.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Schunkert H. The importance of early intervention in CHF- signs and symptom relief.JRAAS 2000;1(suppl 1)17-23.
  • Black HR, Chang PI, Reevers RA, Cooper W., Pouleur H. Monotherapy treatment success rate of omapatrilat, a vasopeptidase inhibitor, compared with lisinopril and amlodipine in mild to moderate hypertension. Am J Hypertens 1999;12: 26A(abstract). 44. Zusman R., Atlas S., Kochlar M., Adler E., Levy E. Efficacy and safety of omapatrilat, a vasopeptidase inhibitor. Am J Hypertens 1999;12:125A(abstract).
  • Neutel J., Shepherd A., Pool J., Levy E., Saini R., Chang PI Antihypertensive efficay of omapatrilat, a vasopeptidase inhibitor, compared with lisonopril. Am J Hypertens 1999;12: 124A(abstract).
  • Rouleau JL, Pfeffer MA, Stewart DJ et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 2000;356:615-20.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hillege HL, Girbes ARJ, De Kam PJ et al. Renal function, neurohormonal activation and survival in patients with chronic heart failure. Circulation 2000;102:203-10.[Abstract/Free Full Text]
  • Important preliminary results presented today from the OVERTURE study with VanlevTM in the treatment of heart failure. Press release on BMS web site (www.bms.com) dated March 20, 2002.
  • Messerli FH, Nussberger J. Vasopeptidase inhibition and angio-oedema. Lancet 2000;356:615-20.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Nussberger J., Cugno M.,Amstutz C., Cicardi M., Pellacani A., Agostoni A. Plasma bradykinin in angio-oedema. Lancet 1998;351:1693-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Bristol-Myers Squibb discloses VanlevTM data from landmark Octave study. Press release on BMS web site (www.bms.com ) dated March 20, 2002.
  • Hu K., Ertl G. Potential role of mixed ACE and neutral endopeptidase inhibitor in the treatment of heart failure. Cardiovasc Res 1999;41:503-5.[Free Full Text]
  • Blais C. Jr, Lapointe N., Rouleau JL, Clement R., Bachvarov DR, Adam A. Effects of captopril and omapatrilat on early post-myocardial infarction survival and cardiac hemodynamics in rats: interaction with cardiac cytokine expression. Can J Physiol Pharmacol 2002;80:48-58.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kostis JB, Cobbe S., Johnston C. et al. Design of the Omapatrilat in Persons with Enhanced Risk of Atherosclerotic events (OPERA) trial. Am J Hypertens 2002;15:193-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 3, No. 2, 90-95 (2002)
DOI: 10.3317/jraas.2002.023
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
J. C. M. Wait, N. Vaccharajani, J. Mitroka, M. Jemal, S. Khan, S. J. Bonacorsi, J. K. Rinehart, and R. A. Iyer
METABOLISM OF [14C]GEMOPATRILAT AFTER ORAL ADMINISTRATION TO RATS, DOGS, AND HUMANS
Drug Metab. Dispos., June 1, 2006; 34(6): 961 - 970.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
A. Clerico, F. A. Recchia, C. Passino, and M. Emdin
Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications
Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H17 - H29.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Sagnella, G. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sagnella, G. A
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Advertisement